1. | G. Dannhardt, S. Laufer und K. Ziereis:
Enaminodiester und -monoester der Pyrrolidin- und Imidazolidin-Reihe. | Arch.Pharm.(Weinheim)
321, 429 (1988) |
2. | G. Dannhardt; S. Laufer und M. Lehr:
HPLC-Determination of Etofenamate and Flufenamic Acid in Biological Material. | Clin.Chem.
34, 2580 (1988) |
3. | G. Dannhardt, S. Laufer:
5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidin. | Synthesis
1989, 12 |
4. | G. Dannhardt, S. Laufer und I. Obergrusberger:
Eine neue Synthese für 3,4-Diarylisoxazolin-5-one und ihre Überführung in 5-(ω-Aminoalkyl)aminoisoxazole und 5-(ß-Aminoethyl)thioisoxazole. | Synthesis
1989, 275 |
5. | G. Dannhardt und S. Laufer:
Ringtransformation von 2-Phenacycliden-imidazolidinen:
Synthese von 5-(ß-Aminoethyl)anilinopyrazolen und
3-(ß-Aminoethyl)aminothiophenen. | Chemiker-Ztg.
113, 290 (1989) |
6. | G. Dannhardt, P. Dominiak and S. Laufer:
Hypertensiv wirksame 5-(ß-Aminoethyl)aminoisoxazole:
Synthese und Testung von Derivaten mit teilrigidisierter C-5-Seitenkette bzw. ω-ständigem Heterocyclus. | Arch. Pharm.(Weinheim)
323, 571 (1990) |
7. | G. Dannhardt, P. Dominiak und S. Laufer:
Hypertensiv wirksame 5-(ω-Aminoalkyl)aminoisoxazole:
Synthese und Prüfung von Verbindungen mit einer Sulfamid- oder Carboxyl-Gruppe am Ende der Seitenkette. | Arch. Pharm. (Weinheim)
323, 517 (1990) |
8. | G. Dannhardt, P. Dominiak und S. Laufer:
Hypertensiv wirksame 5-(ß-Aminoethyl) aminoisoxazole:
Synthese und Testung von Isoxazolopyrazinen und Isoxazoldiazepinen. | Arch.Pharm. (Weinheim)
324, 141-148 (1991 |
9. | G. Dannhardt, P. Dominiak und S. Laufer:
Hypertensive Effects and Structure-Activity-Relationships of 5-ω-Aminoalkylisoxazoles. | Arzneim.-Forsch./Drug Res.
43(I) Nr. 4 (1993)
441-444 |
10. | S.A. Laufer, J. Augustin, G. Dannhardt und W. Kiefer:
(6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, A Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase. | J.Med.Chem.
Vol. 37, 12
1894-1897 (1994 |
11. | Laufer, S. Tries, J. Augustin und G. Dannhardt:
Pharmacological Profile of a New Pyrrolizine Derivative Inhibiting the Enzymes Cyclooxygenase and 5-Lipoxygenase. | Arzneim.-Forsch./Drug Res.
44(I),
Nr. 5 (1994)
629-636 |
12. | S. Laufer, S. Tries, J. Augustin,R. Elsäßer, D.R. Algate
P.R. Atterson und P.L. Munt:
Gastrointestinale Tolerance of [2,2-Dimethyl-6(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic Acid in the Rat. | Arzneim.-Forsch/Drug Res.
44(II),
Nr.12 (1994)
1329-1333 |
13. | S. Laufer, S. Tries, J. Augustin, R. Elsäßer, W. Albrecht
R. Guserle, D.R. Algate, P.R. Atterson und P.L. Munt:
Acute and Chronic Anti-inflammatory Properties of [2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1Hpyrrolizine-5-yl]-acetic Acid. | Arzneim.-Forsch/Drug Res.
45(I),
Nr. 1 (1995)
27-32 |
14. | D.R. Algate, J. Augustin, P.R. Attersson, D.J. Beard,
C.M. Collins, S. Laufer, P.L. Munt und S. Tries:
General Pharmacology of [2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic in Experimental Animals. | Arzneim.Forsch./Drug Res.
45(I), 2, 159-165
(1995) |
15. | H.-P. Deigner, C.E. Freyberg und S. Laufer:
Distribution and Excretion of [14C]-labelled[2,2-Dimethyl-6- (4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl[2’-14C]-acetic Acid in Rats. | Arzneim.-Forsch Drug Res.
45(I), 3, 272-276
(1995) |
16. | A. Heidemann, S. Tries, S. Laufer und J. Augustin:
Studies on the in vitro and in vivo Genotoxicity of [2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1Hpyrrolizine-5-yl] acetic Acid. | Arzneim.-Forsch./Drug Res.
45 (I),
489-490 (1995 |
17. | J.L. Wallace, L. Carter, W. McKnight, S. Tries und S. Laufer:
ML 3000 Reduces Gastric Prostaglandin Synthesis Without Causing Mucosal Injury. | Europ. Journal of Pharmacology
271(1994) 525-531 |
18. | G. Dannhardt, G. Lambrecht, S. Laufer, E. Mutschler, J. Schweiger:
Regioisomeric 5(3)-Aminomethyl-3(5)-Phenyl Isoxazoles:
Synthesis Spectroscopic Discrimination and Muscarinic Activity. | Arch. Pharm. (Weinheim),
328, 437-443 (1995) |
19. | G. Dannhardt, W. Kiefer, G. Lambrecht, S. Laufer E. Mutschler, J. Schweiger, H.-G. Striegel:
Regioisomeric 3-,4- and 5-Aminomethyl Isoxazoles:
Synthesis and Muscarinic Activity. | Eur. J. Med. Chem.30,
839-850 (1995) |
20. | S. Laufer, K. Neher, B. Bayer, J. Homann, E. Reutter,
S. Tries:
In-vitro test system for the evaluation of dual cyclooxygenase and 5-lipoxygenase inhibitors. | Pharm. Pharmacol. Lett
5
(1995) 4: 166-169 |
21. | B. Greve, P. Imming, S. Laufer:
Effiziente Synthese neuer 2-Cycloalk(en)ylpropansäure-Derivate Mittlere Ringe als Bioisostere von Alkylphenylresten. | Angew. Chemie
(1996) 108, 1312-1314 |
22. | K. Doser, R. Guserle, R. Krammer, S. Laufer, K.
Lichtenberger:
Bioequivalence evaluation of two Flutamid 250 mg Preparations in healthy female volunteers. | Arzneim.-Forsch./Drug Res.
47(I), 2, 213-217 (1997) |
23. | A. Kirschning, M. Ries, S. Domann, W. Martin, W. Albrecht, P. Arnold, S. Laufer:
Synthesis and biological identification of the acylglucuronide
of the antiinflammatory drug ML 3000. | Bioorganic and Medicinal Chemistry Letters
(1997), 7, 903-906 |
24. | S. Laufer, H.-G. Striegel, K. Neher, P. Zechmeister, C.Donat, K. Stolingwa, S. Baur, S. Tries, T. Kammermeier, G. Dannhardt,W. Kiefer:
Synthesis and evaluation of a novel series of pyrrolizinederivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors. | Arch. Pharm. Pharm. Med. Chem.
330, 307-312 (1997) |
25. | W.M. Abraham, S. Laufer, S. Tries:
The effects of ML 3000 on antigen-induced responses in sheep. | Pulmonary Pharmacology
& Therapeutics
(1997) 10, 167-173 |
26. | A.Hiermann, H.W. Schramm and S. Laufer:
Anti-inflammatory activity of myricetin-3-O-ß-D-glucuronide and related compounds. | Inflammation Research
47 (1998) 421-427 |
27. | S. Laufer, P. Zechmeister, T. Klein:
Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors. | Inflammation Research
48 (1999) 133-138 |
28. | G. Dannhardt and S. Laufer:
Structural approaches to explain the selectivity of COX-2 inhibitors:
Is there a common pharmacophore ? | Current Medicinal Chemistry
(2000), 7, 1101-1112 |
29. | Abadi A H, Laufer S, Lehmann J:
Synthesis and Cyclooxygenase inhibitory properties of Novel (+)2-(6-Methoxy-2-naphthyl)propionic Acid Derivates. | Arch. Pharm. Pharm. Med Chem.
2001, 334:(3)104-6 |
30. | Bracher, F.; Krauss, J.; Laufer, S.:
Effects of natural products containing acylresorcinol partial structures on cyclooxygenases and 5-lipoxygenase. | Pharmazie
5/2001 |
31. | Fabio Celotti and Stefan Laufer:
Anti-Inflammatory Drugs: New Multitarget Compounds To Face An Old Problem. The Dual Inhibition Concept. | Pharmacological Research
Vol. 43, No. 5, 429-436
(2001) |
32. | Stefan Laufer:
Discovery and Development of ML3000. | Inflammo- Pharmacology
Vol. 9, No. 1-2, pp. 101-112
(2001) |
33. | Susanne Tries and Stefan Laufer:
The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. | Inflammo- Pharmacology
Vol. 9, No. 1-2, pp. 113-124
(2001) |
34. | Renate E. Gay, Michel Neidhart, Ferenc Pataky, Susanne Tries, Stefan Laufer and Steffen Gay:
Dual Inhibition of 5-Lipoxygenase and Cyclooxygenase-1/-2 by ML3000 reduces Joint Destruction in Adjuvant Arthritis. | Journal of Rheumatology
28(9): 2060-5 (2001) |
35. | Christoph A. Klaas, Gerd Wagner, Stefan Laufer, Silvio Sosa, Roberto Della Loggia, UlrichBomme, Heike L. Pahl and Irmgard Merfort:
Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers. | Planta Medica
2002;68: 385-391 |
36. | Dragan V. Jovanovic, Julio C. Fernandes, Vicorica Lascau-Coman, Johanne Martel-Pelletier, Pascal Reboul, Stefan Laufer, Susanne Tries and Jean-Pierre Pelletier:
The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental ostheoarthritis. Suppression of collagenase-1 and interleukin-1b. | Arthritis and Rheumatism
14(10): 2320-2330 (2001) |
37. | Paredes, Y., Massicotte, F., Pelletier, J-P., Martel-Pelletier, J., Laufer, S., Lajeunesse, D.:
Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritic osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. | Arthritis & Rheumatism
46(7): 1804-1812 (2002) |
38. | He, W., Pelletier, J-P., Martel-Pelletier, J., Laufer, S., Di Battista, J.A.:
The synthesis of interleukin-1ß, tumour necrosis factor-a and interstitial collagenase (MMP-1) is eicosanoid dependent in human OA synovial membrane explants: interactions with anti-inflammatory cytokines. | The Journal of Rheumatology
2002: 29:3, 546-553 |
39. | S. Tries, W. Neupert and S. Laufer:
The mechanism of action of the new gastric sparing antiinflammatory
compound ML3000: inhibition of COX and 5-LOX. | Inflammation Research
51 (2002) 135-143 |
40. | S. Tries, S. Laufer, P. Radziwon and H. K. Breddin:
Antithrombotic and platelet function inhibiting effects of ML3000, a gastric sparing new antiinflammatory drug with COX / 5-LOX inhibitory activity. | Inflammation Research
51 (2002) 129-134 |
41. | Christelle Boileau, Johanne Martel-Pelletier, Jean-Yves Jouzeau, Patrick Netter, Florina Moldovan, Stefan Laufer, Susanne Tries and Jean-Pierre Pelletier:
Licofelone (ML3000), a Dual Inhibitor of 5-Lipoxygenase and Cyclooxygenase, Reduces the Level of Cartilage Chondrocyte Death In Vivo in Experimental Dog Osteoarthritis: Inhibition of Pro-Apoptotic Factors. | The Journal of Rheumatology
2002; 29:7; 1446-1453 |
42. | Stefan A. Laufer and Gerd K. Wagner:
From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release. | Journal of MedicinalChemistry
2002, 45(13), 2733-2740 |
43. | S. Laufer, D. Kotschenreuther, and G. Wagner:
Ones, Thiones and N-Oxides: An Exercise in Imidazole Chemistry. | Angewandte Chemie Int. Edition
2002,41,No.13, 2290-2293 |
44. | S. Laufer, C. Greim, T. Bertsche:
A in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. | OA & Cartilage
2002, 10(12):961-967 |
45. | Stefan A. Laufer, Hans-Günther Striegel and Gerd K. Wagner:
Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position. | Journal of Medicinal Chemistry
2002, 45(21), 4695-4705 |
46. | Stefan A. Laufer, Dunja A. Kotschenreuther, Gerd K. Wagner and Wolfgang Albrecht:
Novel Substituted Pyridinyl Imidazoles as Potent Anti-Cytokine Agents with Low Cytochrome P450 Activity. | Journal of Medicinal Chemistry
2003, 46(15), 3230-44 |
47. | D Lajeunesse, J Martel-Pelletier, J C Fernandes, S Laufer, and J-P Pelletier:
Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis. | Annals of Rheumatic Diseases
2004; 63 (1): 78-83 |
48. | Stefan A. Laufer, Dunja Kotschenreuther and Gerd K. Wagner:
Identification of Regioisomers in a Series of N-Substituted
Pyridin-4-yl-imidazole Derivatives by Regiospecific Synthesis, GC/MS and 1H-NMR. | J. Org. Chem.
68, 4527-4530 (2003) |
49. | I. Wagner, C. Greim, S. Laufer, C. Gleiter and L. Heide:
Influence of willow bark extract on cyclooxygenase activity and on TNFa or IL-1ß release in vitro and ex vivo | Clinical Pharmacology and
Therapeutics
73/3, S. 272-274 (2003) |
50.
| Stefano Fiorucci, Eleonora Distrutti, Andrea Mencarelli, Antonio Morelli, Stefan A. Laufer and John L Wallace :
Evidence that 5-lipoxygenase and acetylated cycloxygenase-2 derived eicosanoids regulate leukocytesendothelial adherence in response to aspirin | Brit. J. Pharmacol.
(2003) 139,1351-1359
|
51.
| Jan M Schwab, Hermann J Schluesener, Stefan Laufer:
COX-3: Just another COX or the solitary elusive target of paracetamol?
| The Lancet
361, 981-2 (2003)
|
52.
| Thomas Scior, Iván Meneses Morales, Solón Javier Garcés Eisele, David Domeyer, Stefan Laufer:
Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis - A Review
| Arch Pharm Pharm Med Chem
335 (11-12), 511-525 (2002)
|
53.
| Kartasasmita RE, Laufer S, Lehmann J:
NO-donors (VII [1]): Synthesis and cyclooxygenase inhibitory properties of N- and S-nitrooxypivaloyl-cysteine derivatives of naproxen - A novel type of NO-NSAID
| Arch Pharm Pharm Med Chem
335 (8): 363-366 (2002)
|
54.
| Laufer Stefan:
Role of Eicosanoids in Structural Degradation in Osteoarthritis.
Invited Review
| Current Opinion inRheumatology
2003; 15(5):623-627
|
55.
| Jan M. Schwab, MDPhD, Thomas Beiter, TA, Juergen U. Linder, PhD, Stefan Laufer, PhD, Joachim E. Schultz, PhD, Richard Meyermann, MD, Hermann J. Schluesener, MDPhD:
COX-3 – a virtual pain target in human?
| FASEB Journal
2003; Vol. 17, No. 15,
2174-2175
|
56.
| Stefan Laufer:
Osteoarthritis therapy—are there still unmet needs?
| Rheumatology
2004;43(Suppl. 1): i9-i15
|
57.
| Jean-Pierre Pelletier, Christelle Boileau, Julie Brunet, Martin Boily, Daniel Lajeunesse, Pascal Reboul, Stefan Laufer and Johanne Martel-Pelletier:
The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of mmp-13 and cathepsin k.
| Bone
2004; 34(3):527-538
|
58.
| Patrick Marcouiller, Jean-Pierre Pelletier, Mélanie Guévremont, Johanne Martel-Pelletier, Pierre Ranger*, Stefan Laufer** and Pascal Reboul:
Leukotreine and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1-beta synthesis.
| Journal of Rheumatology
(2005), 32 (4), 704-721
|
59.
| Peter Bias, M.D., Anton Buchner, Ph.D., Bernhard Klesser, M.D., Stefan Laufer, Ph.D:
The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial
| The American Journal
of Gastroenterology
99 (4): 611-618 (2004) |
60.
| Bernd Kammerer, Rainer Kahlich, Stefan Laufer and Christoph C. Gleiter:
Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionization tandem mass spectrometry | Rapid Communications in
Mass Spectrometry
2004; 18:458-464
|
61.
| Philipp A. Lang1, Daniela S. Kempe1, Swetlana Myssina1, Christina Birka1, Stefan Laufer2, Florian Lang1, Thomas Wieder1, Stephan M. Huber1 :
PGE2 in the regulation of programmed erythrocyte death | Cell Death andDifferentiation
12(5): 415-428 (2005) |
62. | M. Günther, S. Laufer and P.C. Schmidt:
High Anti-inflammatory Activity of Harpagoside Enriched Extracts obtained from Solvent Modified Super- and Subcritical Carbon Dioxide Extraction of the Roots of Harpagophytum procumbens. | Phytochemical Analysis
17: 1-7 (2006) |
63. | Ulbrich, H., Xie, X., Söhnlein, O., Eriksson, E.E., Lindbom, L. Albrecht, W., Laufer S. and Dannhardt, G.:
Licofelone, a novel 5-LOX/COX -inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow
| Biochemical Pharmacology
70(1): 30-36, 2005
|
64.
| Bernd Kammerer, Rainer Kahlich, Stefan Laufer, Shuming Li, Lutz Heide and Christoph H. Gleiter:
Mass spectrometric pathway monitoring of secondary metabolites - Systematic analysis of culture extracts of Streptomyces species
| Analytical Biochemistry
(2004), 335, 17-29
|
65.
| Stefan A. Laufer,*,† David M. Domeyer,† Thomas R. F. Scior,‡ Wolfgang Albrecht,¦ Dominik R. J. Hauser†:
Synthesis and Biological Testing of Purine Derivatives as Potential ATP-Competitive Kinase-Inhibitors | Journal of MedicinalChemistry
(2005), 48, 710-722 |
66.
| Stefan A. Laufer* , Simona Margutti and Martina D. Fritz:
Substituted Isoxazoles as Potent Inhibitors of p38 MAP Kinase
| ChemMedChem,
Volume 1, Issue 2, 2006.
197-2007
|
67.
| Stefan A. Laufer*,†; Hans-Günther Striegel‡; Werner
Zimmermann†; Kathrin J. Ruff†:
Tetrasubstituted Imidazole Inhibitors of Cytokine Release: Probing Substituents in the N-1 Position
| Journal of Medicinal
Chemistry
(2004), 47, 6311-6325
|
68.
| Christelle Boileau, PhD1; Jean-Pierre Pelletier, MD1; Ginette Tardif, PhD1; Hassan Fahmi, PhD1; Stefan Laufer, PhD2; Martin Lavigne, MD3; Johanne Martel-Pelletier, PhD1.:
THE REGULATION OF HUMAN MMP-13 BY LICOFELONE, AN INHIBITOR OF CYCLOOXYGENASES AND 5-LIPOXYGENASE, IN HUMAN OSTEOARTHRITIC CHONDROCYTES IS MEDIATED BY THE INHIBITION OF THE p38 MAP KINASE SIGNALING PATHWAY.
| Annals of the Rheumatic
Diseases
(2005);64:891-898
|
69.
| Johanne Martel-Pelletier, PhD1,2; François Mineau, MSc1; Hassan Fahmi, PhD1,2; Stefan Laufer, PhD3; Pascal Reboul, PhD1,2; Christelle Boileau, PhD1; Martin Lavigne, MD4; and Jean-Pierre Pelletier, MD1,2:
REGULATION OF THE EXPRESSION OF FLAP/5-LOX AND SYNTHESIS OF LTB4 IN OSTEOARTHRITIC CHONDROCYTES: ROLE OF TGF-ß AND EICOSANOIDS. | Arthritis & Rheumatism
50 (12): 3925-3933 (2004)
|
70.
| Steinhilber, D., Laufer, S.:
DPHG-Expertenmeinung - Rofecoxib und die anderen coxibe.
| (2004) Deutsche
Apotheker Zeitung,
144 (45), 30-32.
|
71.
| Stefan Laufer, Sabine Thuma, Cornelia Greim, Yvonne Herweh, Angela Albrecht and Frank Dehner:
An immunosorbent, non radioactive p38 MAP kinase assay comparable to standard radioactive lipuid phase assays.
| Analytical Biochemistry
344 (2005) 135-137
|
72.
| Jean-Pierre Pelletier,1 Christelle Boileau, Martin Boily, Julie Brunet, François Mineau, Changshen Geng, Pascal Reboul, Stefan Laufer,2 Daniel Lajeunesse, and Johanne Martel-Pelletier1:
THE PROTECTIVE EFFECT OF LICOFELONE ON EXPERIMENTAL OSTEOARTHRITIS IS CORRELATED WITH THE DOWNREGULATION OF THE GENE EXPRESSION AND THE PROTEIN SYNTHESIS OF SEVERAL MAJOR CARTILAGE CATABOLIC FACTORS: MMP-13, CATHEPSIN K, AND AGGRECANASES.
| Arthritis Research & Therapy
7 (5): R1091-R1102 2005
|
73.
| Kammerer B, Kahlich R, Ufer M, Laufer S, Gleiter Ch:
Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism.
| Analytical Biochemistry
(2005), 339 (2): 297-309
|
74. | Dieter Schollmeyer, Bernd Kammerer, Christian Peifer, Stefan Laufer:
3(RS)-Bromo-3-[1(SR)-phenyl-propyl]-chroman-2,4-dione | Acta Cryst. 2005, E61
o868-o869
|
75.
| Bernd Kammerer, Antje Frickenschmidt, Stefan Laufer, Christoph H. Gleiter, Hartmut Liebich:
„MALDI-TOFMS Analysis of Urinary Nucleosides”
| JOURNAL OF THE AMERICAN SOCIETY FOR
MASS SPECTROMETRY
16 (6): 940-947 JUN 2005
|
76.
| Kahlich R, Gleiter CH, Laufer S, Kammerer B.
Quantitative determination of piritramide in human plasma and urine by off- and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry.
| Rapid Commun Mass
Spectrom.
2006;20(2):275-283
|
77.
| Scior, T., Guevara-García, A., Bernard, P., Do, Q.-T., Domeyer, D., Laufer, S.:
Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: A critical review.
| Mini-Reviews in Medicinal
Chemistry
(2005)
5 (11), Pages 995-1008
|
78.
| J. Martel-Pelletier, G. Tardif, S. Laufer and J.-P. Pelletier:
Cytokines and Growth Factors in the Treatment of Osteoarthritis: What could bet he Best Disease Modifying Drugs.
| Curr. Med. Chem.Anti-Inflammatory& Anti-
Allergy Agents
2005, 4, 235-249
|
79. | Gerd Wagner and Stefan Laufer:
Small Molecular Anti-Cytokine Agents | Medicinal Research Reviews
2006, 26 (1), pp 1-62 |
80.
| M.T.Lindenmeyer, A.Hrenn, C.Kern, V.Castro, R.Murillo, S.Müller, S.Laufer, J.Schulte-Mönting, B.Siedle, I.Merfort:
Sesquiterpene Lactones as Inhibitors of IL-8 Expression in HeLa Cells
| Bioorganic and Medicinal
Chemistry (2006)
14 (8), pp. 2487-2497
|
81. | Bernd Kammerer, Mike Ufer, Andreas Schenkel, Stefan Laufer, Christoph H. Gleiter, Rainer Kahlich:
Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes",
| Analytical and Bioanalytical Chemistry
(2005), 383 (6) 909-917
|
82.
| Bernd Kammerer, Antje Frickenschmidt, Christa E. Müller, Stefan Laufer, Christoph H. Gleiter and Hartmut Liebich:
“Mass spectrometric identification of modified urinary nucleosides as potential biomedical markers by LC-ITMScoupling”
| Analytical and Bioanalytical Chemistry
(2005), 382(4), 1017-1026
|
83.
| Treiber G, Wex T, Alexander L, Vieth M, Laufer S,Malfertheiner P:
"The Effect of Single Dose Naproxen on Eicosanoid Formation in Human Gastroduodenal Mucosa".
| (APT-0511-2005.R1) Alimentary Pharmacology & Therapeutics
2006 Jan 1;23(1):155-67
|
84.
| Germann I, Hagelauer D, Kelber O, Vinson B, Laufer S,Weiser D, Heinle H.:
Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast((R))).
| Phytomedicine
13: 45-50 Suppl. 1, 2006
|
85. | Maxim Moreau, Christelle Boileau, Johanne Martel-Pelletier, Julie Brunet, Stefan Laufer and Jean-Pierre Pelletier:
Licofelone reduces the progression of structural changes in
a canine model of ostheoarthritis under curative conditions:
Effect on protease expression and activity | The Journal of Rheumatology
2006; 33:6, 1176-1182
|
86.
| Christian Peifer, Sabine Luik, Sabine Thuma, Yvonne Herweh and Stefan Laufer:
Development and optimization of a non radioactive JNK3 assay
| COMBINATORIAL CHEMISTRY AND HIGH THROUGHPUT SCREENING
2006, 9 (8), 613-618.
|
87.
| Peifer C, Wagner G, Laufer S.:
New Approaches to the Treatment of Inflammatory Disorders Small Molecule Inhibitors of p38 MAP Kinase. | Curr Top Med Chem.
2006;6(2):113-49.
|
88.
| Bullinger, Dino; Frickenschmidt, Antje; Pelzing, Matthias; Zey, Thomas; Zurek, Gabriela; Laufer, S.; Kammerer, Bernd:
Identification of urinary nucleosides by ESI-TOF-MS.
| LC-GC Europe
(2005), 16-17. CODEN: LCGCB4 ISSN:1471-6577. AN 2005:1351965 CAPLUS
|
89.
| Christian Peifer, Stefanie Laudage, Dieter Schollmeyer and Stefan Laufer:
3-(4-Fluorophenyl)-4-pyridin-4-ylquinolin-2(1H)-one.
| Acta Cryst. 2006, E62,
2475-2477.
|
90.
| Christian Peifer, Dieter Schollmeyer, Roland Selig and Stefan Laufer:
4-(4-Fluorophenyl)-3-(4-pyridin)quinolin-2(1H)-one.
| Acta Cryst. 2006, E62,
2648-2650.
|
91.
| Christian Peifer, Mohammed Abadleh, Dieter Schollmeyer and Stefan Laufer:
4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridine.
| Acta Cryst. (2006). E62,
o3647–o3649
|
92.
| Stefan A. Laufer* and Andy J. Liedtke:
A concise and optimized four-step approach toward 2-(aryl-)alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles using alkyl- or arylalkyl thiocyanates. | Tetrahedron Letters
(2006),
doi:10.1016/j.tetlet.2006.07.147.
|
93.
| Christian Peifer, Mohammed Abadleh, Dieter Schollmeyer and Stefan Laufer:
4-[3-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridine
| Acta Cryst. (2006). E62,
o3707–o3709 |
94.
| Ekaterina Shumilina1, Valentin Kiedaisch1, Ahmad Akkel1, Philipp A. Lang1, Tobias Hermle, Daniela S. Kempe, Stephan M. Huber, Thomas Wieder, Stefan Lauffer, Florian Lang:
Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884
| Cellular Physiology and Biochemistry (2006)
18 (4-5): 233-242 |
95.
| Stefan Laufer and Sabine Linsenmaier:
Development of a Microsphere-Based p38α MAP Kinase No-Wash Assay
| Journal of Biomolecular Screening (2006)
11(5); 528-536
|
96.
| Christian Peifer, Mohammed Abadleh, Dieter Schollmeyer and Stefan Laufer:
3,4-bis(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide
| Acta Cryst. (2006). E62,
o4827–o4828
|
97.
| Christian Peifer, Agata Krasowski, Nina Hämmerle, Oliver Kohlbacher, Gerd Dannhardt, Frank Totzke, Christoph Schächtele and Stefan Laufer:
Profile and Molecular Modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione as a Highly Selective VEGF-R2/3 Inhibitor
| Journal of Medicinal Chemistry
2006, 49, 7549-7553
|
98.
| Stefan A. Laufer*, Gabriele M. Ahrens, Solveigh C. Karcher, Jörg S. Hering, Raimund Niess:
Design, synthesis and biological evaluation of phenylaminosubstituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: Novel p38 MAP Kinase Inhibitors
| Journal of Medicinal Chemistry
2006, 49, 7912-7915
|
99.
| Christian Peifer, OliverWerz, Daniel Poeckel, Dieter Schollmeyer and Stefan Laufer:
(4 R)-4-Hydroxy-1-[(2 S)-2-hydroxydodecyl]-L-proline monohydrate
| Acta Cryst. (2006). E62,
o5138–o5140
|
100.
| Christian Peifer+*, Katrin Kinkel+, Mohammed Abadleh+,
Dieter Schollmeyer§ and Stefan Laufer+:
From five to six membered rings: 3,4-Diarylquinolinone as
Lead for Novel p38MAP Kinase Inhibitors.
| Journal of Medicinal Chemistry
2007, 50, 1213-1221
|
101. | Dominik R. J. Hauser,† Thomas Scior,§ David M.
Domeyer,† Bernd Kammerer,‡ Stefan A. Laufer,*,†: Synthesis, Biological Testing and Binding Mode Prediction of 6,9-Diaryl-purine-8-ones as p38 MAP Kinase Inhibitors
| Journal of Medicinal Chemistry
2007, 50, 2060-2066
|
102. | Christian Peifer, Roland Selig, Dieter Schollmeyer and Stefan Laufer:
N-_( Z)-2-[1-(Triisopropylsilyl)-1H-indol-3-yl]-2- (triisopropylsilyloxy)vinyl _-2-(3,4,5-trimethoxyphenyl)acetamide
| Acta Cryst. (2007)
E63, o1266–o1268
|
103. | Christian Peifer, Melanie Tschertsche, Dieter Schollmeyer and Stefan Laufer:
(1a R,2a S,5a S,5b S)-Perhydro-4Hoxireno[3,4]cyclopenta[1,2- b]furan-4-one
| Acta Cryst. (2007). E63,
o1359–o1360 |
104. | Christian Peifer, Dimitri Ott, Dieter Schollmeyer and Stefan Laufer:
Ethyl (2,3-dihydro-1H,1_ H-2,3_-biindol-1-yl)glyoxylate
| Acta Cryst. (2007). E63,
o1415–o1417
|
105. | Mohammed Abadleh, Christian Peifer, Katrin Kinkel, Dieter Schollmeyer and Stefan Laufer:
4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridin-2(1H)- one
| Acta Cryst. (2007). E63,
o1423–o1425 |
106. | Bernd Kammerer, Holger Scheible, Gabriela Zurek, Markus Godejohann, Klaus-Peter Zeller, Christoph H. Gleiter, Wolfgang Albrecht and Stefan Laufer:
“On-line analytical techniques for comprehensive metabolite identification: LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS for direct analysis of metabolites from in vitro studies”
| Xenobiotica (2007)
37 (3): 280-297
|
107. | Kammerer, B., Scheible, H., Albrecht, W., Gleiter, C. H. and Laufer, S.:
“Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor”
| Drug Metabolism and Disposition (2007)
35 (6): 875-883 |
108. | Christian Peifer, Dieter Schollmeyer, Melanie Tschertsche and Stefan Laufer:
rac-(3 E,3a R,6a R)-3-(Hydroxymethylene)-3,3a,6,6atetrahydro-
2Hcyclopenta[b]furan-2-one
| Acta Cryst. (2007). E63,
o1551–o1553
|
109. | Dott. Simona Margutti, Prof. Dr. Stefan A. Laufer:
Drug Discovery Targets Are MAP Kinases Drug Targets? Yes, but Difficult Ones
| ChemMedChem (2007)
2, 1116 - 1140
|
110.
| Katrin Kinkel, Stefan Laufer, Dieter Schollmeyer and Christian Peifer:
2,2-Dimethyl-N-[3-(3,4,5-trimethoxybenzoyl)pyridin-4- yl]propanamide | Acta Cryst. (2007). E63,
o1887–o1889 |
111. | Peifer, C.*, Schollmeyer, D., Tschertsche, M. and Laufer, S.:
(2aRS,3RS,4aSR,6aRS,6bSR)-3-Hydroxy-2a,3,4a,6,6a,6bhexahydro-1,4-dioxacyclopenta[cd]pentalen-2(5H)-one.
| Acta Cryst. (2007). E63,
2249-2251.
|
112. | Christian Peifer, Dieter Schollmeyer, Katrin Kinkel and Stefan Laufer:
3-(4-Fluorophenyl)-1-methyl-4-(4-pyridyl)quinolin-2(1H)-one
| Acta Cryst. (2007). E63,
o2457–o2459
|
113. | Abu Thaher, Bassam, Schollmeyer, Dieter, Laufer, Stefan:
2-(4-Fluorophenyl)-1-(4-pyridyl)cydo-pentan-1-ol
| Acta Cryst. (2007). E63,
o3531-33
|
114. | Caroline Ospelt*, Mariola Kurowska-Stolarska*, MichelNeidhart*, Beat A. Michel*, Renate E. Gay*, Stefan Laufer† and Steffen Gay*:
The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands
| Annals of the Rheumatic Diseases (2008)
67 (4), 524-529
|
115. | Helga U Joos, Wolfgang Albrecht, Stefan Laufer, Heiko Reichel and Rolf E Brenner:
IL-1 beta Regulates Expression of Cytoskeleton Related Genes in Human Osteoarthritic Chondrocytes wherein p38 MAPK is partially involved | Molecular Medicine (2008)
14 (3-4), 150-159
|
116. | Stefan Laufer* and Pierre Koch:
Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity
| Organic & Biomolecular Chemistry (2008)
6, 437 - 439.
|
117. | Dr. Irmgard Merfort; Frank Gvtschel; Claudia Kern; Simona Lang; Titus Sparna; Cordula Markmann; Joseph Schwager; Sabine McNelly; Fritz von Weizsdcker; Stefan Laufer; Andreas Hecht:
Inhibition of glycogen synthase kinase 3 leads to differential modulation of several signaling pathways in primary murine hepatocytes but fails to promote TNF-alpha-induced apoptosis
| Experimental Cell Research
(2008)
314, 1351-1366
|
118. | Stefan A. Laufer,* Dominik R. J. Hauser, Andy J. Liedtke: Regiospecific and Highly Flexible Synthesis of 1,4,5- Trisubstituted 2-Sulfanylimidazoles from Structurally Diverse
Ethanone Precursors, Highly Substituted Pyridinylimidazole- Based p38 MAP Kinase Inhibitors
| Synthesis (2008)
No. 2, 0253-0266 |
119. | Bassam Abu Thaher,a Pierre Koch,b Vicente Del Amo,c
Paul Knochel,c Stefan Laufer*:
A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-
pyridyl)cyclopentene from Cyclopentanone
| Synthesis (2008)
No. 2, 0225-0228
|
120. | Peifer, C.*, Selig, R., Kinkel, K., Ott, D., Totzke, F., Schächtele, C, Heidenreich, R., Röcken, M., Schollmeyer, D. and Laufer, S.:
Design, Synthesis and Biological Evaluation of Novel 3,4-
Diaryl-2H-Pyrrole-2-ones as VEGF-R inhibitors.
| Journal of Medicinal Chemistry (2008)
10;51(13):3814-24
|
121. | Peifer, C.*, Urich, R., Schattel, V., Abadleh, M., Röttig, M., Kohlbacher, O. and Laufer, S.:
Implications for selectivity of 3,4-Diarylquinolinones as p38α
MAP Kinase inhibitors.
| Bioorg. Med. Chem. Letters (2008)
(18) 1431-1435
|
122. | Buehler, S., Schollmeyer, D., Hauser, D., Laufer, S. and Peifer, C. *:
2-(6-Amino-7H-purine-7-yl)-1-phenylethanone.
| Acta Cryst. (2007) E63,
4646-4647. |
123. | Buehler, S., Schollmeyer, D., Hauser, D., Laufer, S. and Peifer, C.:
2-(6-Methoxy-7H-purine-7-yl)-1-phenylethanone monohydrate. | Acta Cryst. (2007) E63,
4154-4155.
|
124. | Simona Tavolari, Massimiliano Bonafè, Marina Marini, Carla Ferreri, Giovanna Bartolini, Elisa Brighenti, Sonia Manara, Vittorio Tomasi, Stefan Laufer and Tiziana Guarnieri*:
Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade
| Carcinogenesis (2008)
29 (2), 371-380
|
125. | Laufer, Stefan; Margutti, Simona:
Isoxazolone based inhibitors of p38 MAP kinase
| Journal of Medicinal Chemistry (2008)
51 (8), 2580-2584 |
126. | Laufer, Stefan; Hauser, Dominik; Domeyer, David; Kinkel, Katrin; Liedtke, Andy:
Design, synthesis, and biological evaluation of novel tri- and
tetrasubstituted imidazoles as highly potent and specific
ATP-mimetic inhibitors of p38 MAP kinase: Focus on
optimized interactions with the enzyme’s surface-exposed
front region
| Journal of Medicinal Chemistry (2008)
51 (14), 4122-4149
|
127. | Valerie S. Honndorf, Nicolas Coudevylle, Stefan Laufer, Stefan Becker and Christian Griesinger*:
Dynamics in the p38α MAP Kinase-SB203580 Complex Observed by liquid state NMR
| Angew.Chemie Int. Ed. (2008)
47 (19), 3548-3551
|
128. | Dino Bullinger, Hans Neubauer, Tanja Fehm, Stefan Laufer, Christoph H. Gleiter and Bernd Kammerer:
Metabolic signature of breast cancer cell line MCF-7: Profiling of modified nucleosides via LC-IT MS coupling
| BMC Biochemistry (2007)
(8), 25
|
129. | Simona Margutti, Dieter Schollmeyer and Stefan Laufer:
4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-
yl]-1-methylpyridinium iodide–4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-4-yl]-1-methylpyridinium iodide (0.6/0.4) | Acta Cryst. (2008) E64
o298-o299
|
130. | Simona Margutti, Dieter Schollmeyer and Stefan Laufer:
4-(4-Fluorophenyl)-2-methyl-3-(1-oxypyridin-4-yl)isoxazol-
5(2H)-one
| Acta Cryst. (2008) E64
o504
|
131. | Antje Frickenschmidt, Holger Fröhlich, Dino Bullinger, Andreas Zell, Stefan Laufer, Christoph H. Gleiter, Hartmut Liebich and Bernd Kammerer:
“Metabonomics in cancer diagnosis: Mass spectrometry based profiling of urinary nucleosides from breast cancer patients”
| Biomarkers (2008)
13 (4): 435-449
|
132. | Wolfgang Albrecht, Anke Unger, Andreas K Nuessler, and Stefan Laufer:
In vitro metabolism of Licofelone (ML3000), an Inhibitor of Cyclooxygenases-1 and -2 and 5-Lipoxygenase
| DMD (2008)
36 (5), 894-903 |
133. | Melanie Holm, Dieter Schollmeyer and Stefan Laufer:
3-(2-Fluorophenyl)-6-(phenoxymethyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole
| Acta Cryst. (2008) E64
o700
|
134. | Frank Lehmann, Dieter Schollmeyer and Stefan Laufer:
6-Amino-1-benzyl-4-(4-chlorophenyl)-3-(4-pyridyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
| Acta Cryst. (2008) E64
o701 |
135. | Dino Bullinger, Holger Fröhlich, Fabian Klaus, Hans Neubauer, Antje Frickenschmidt, Carsten Henneges, Andreas Zell, Stefan Laufer, Christoph H. Gleiter, Hartmut Liebich and Bernd Kammerer:
„Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer”
| Analytica Chimica Acta (2008)
618 (1): 29-34
|
136. | Lehmann, Frank; Holm, Melanie, Laufer, Stefan:
"Three-Component Combinatorial Synthesis of Novel Dihydropyrano[2,3-c]pyrazoles"
| Journal of Combinatorial Chemistry (2008)
10 (3), 364-367
|
137. | Stefan Laufer, Cornelia Greim, Sabine Luik, Samir S Ayoub and Frank Dehner:
Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-2 activity
| Inflammopharmacology (2008)
16 (2008) 155-161
|
138. | Pierre Koch, Christiane Bäuerlein, Hartmut Jank and Stefan Laufer*:
Targeting the Ribose and Phosphate Binding Site of p38 MAP Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles
| Journal of Medicinal Chemistry (2008)
51 (18), 5630-5640
|
139. | Zurek, G.; Krebs, I; Goetz, S.; Scheible, H.; Laufer, S.; Kammerer, B.; Albrecht, W.:
Smart Formula 3D accelerates drug elucitation automatic formulae determination with ESI-TOF mass spectrometry
| LC GC EUROPE (2008)
Suppl. S, 31-33
|
140.
| Andreas Koeberle, Ulf Siemoneit, Ulrike Bühring, Hinnak Northoff, Stefan Laufer, Wolfgang Albrecht and Oliver Werz:
Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1
| JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
326 (3). 975-982
|
141. | Koch, P.; Bäuerlein, C.; Schollmeyer, D.; Laufer, S.:
Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-
ylsulfanyl]butanoate
| Acta Cryst. (2008) E64
o1183-o1184
|
142. | Christian Peifer, Stefanie Bühler, Dominik Hauser, Katrin Kinkel, Frank Totzke, Christoph Schächtele and Stefan Laufer:
Design, synthesis and characterization of N9/N7-substituted
6-aminopurines as VEGF-R and EGF-R inhibitors
| Europ. J. Med. Chem.
(2009)
44, 1788-1793
|
143. | Bullinger, D., Fux, R., Nicholson, G., Plontke, S., Belka, C., Laufer, S., Gleiter, C. H., Kammerer, B.:
Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis
| Journal of the American Society for Mass Spectrometry (2008)
19 (10), 1500-1513 |
144. | Jalal A. Zahra, Mustafa M. El-Abadelah, Bassam A. Abu Thaher, Stefan Laufer and Roland Boese:
Facile Synthesis of Model Indazolo[2,1-c][1,3,4]Bbenzotriazepin-5,13-diones
| Heterocycles 2008-07-10
75 (12),
|
145. | J-P Raynauld, J Martel-Pelletier, P Bias, S Laufer, B Haraoui, D Choquette, A D Beaulieu, F Abram, M Dorais, E Vignon, J-P Pelletier:
Protective Effects of Licofelone, a 5-Lipoxygenase and Cyclooxygenase Inhibitor, vis-a-vis Naproxen in Knee Osteoarthritis: A Two Year Study Using Quantitative MRI
| ANN RHEUM DIS (2008)
Doi:
10.1136/ard.2008.088732
26.07.2008
66, 59-59, Suppl. 2
|
146. | Pierre Koch, Dieter Schollmeyer and Stefan Laufer:
tert-Butyl N-(4-methyl-2-pyridyl)carbamate
| Acta Cryst. (2008) E64
o2216
|
147. | Pierre Koch, Dieter Schollmeyer and Stefan Laufer:
tert-Butyl N-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl]carbamate
| Acta Cryst. (2008) E64
o2221
|
148. | Pierre Koch, Dieter Schollmeyer and Stefan Laufer:
tert-Butyl N-benzyl-N-(4-methyl-2-pyridyl)carbamate
| Acta Cryst. (2008) E64
o2222
|
149. | Michael Föller, Hasan Mahmud, Shuchen Gu, Kan Wang, Elisa Floride, Yulia Kucherenko, Sabine Luik, Stefan Laufer, Florian Lang:
PARTICIPATION OF LEUKOTRIENE C4 IN THE REGULATION OF SUICIDAL ERYTHROCYTE DEATH
| J. Physiology and Pharmacology
In Press
|
150.
| Zahra JA, El-Abadelah MM, Abu Thaher BA, Laufer S, Boese R:
FACILE SYNTHESIS OF MODEL INDAZOLO[2,1-
c][1,3,4]BENZO-TRIAZEPINE-5,13-DIONES
| HETEROCYCLES (2008)
75 (12), 2989-3004
|
151. | Stefan Laufer and Frank Lehmann:
Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase | Bioorg. Med. Chem. Lett.
(2009)
19: 5, 1461-1464
|
152. | Schmidt C.; Fronza, M.; Goettert M., Geller F.; Luik, S; Flores E.M.M.; Bittencourt C.F.; Zanetti G.D., Heinzmann B.M., Laufer S., Merfort I.:
Biological studies on Brazilian plants used in wound healing Journal of Ethnopharmacology
| Journal of Ethnopharmacology (2009)
122, 523–532
|
153. | Solveigh C. Karcher and Stefan A. Laufer:
Aza-Analogue Dibenzepinone Scaffolds as p38 Mitogenactivated Protein Kinase Inhibitors: Design, Synthesis and Biological Data of Inhibitors with Improved Physicochemical Properties
| Journal of Medicinal Chemistry (2009)
52: 6, 1778-1782
|
154. | Frank Lehmann, Melanie Holm and Stefan Laufer:
Rapid and Easy Access to Indoles via Microwave-assisted Hemetsberger-Knittel Synthesis
| Tetrahedron Letters (2009)
50: 15, 1708-1709
|
155. | Bassam Abu Thaher, Pierre Koch, Verena Schattel, and Stefan Laufer:
The role of the hydrogen bonding heteroatom-Lys53 interaction between the p38α Mitogen-Activated Protein (MAP) kinase and pyridinylsubstituted 5-membered heterocyclic ring inhibitors | Journal of Medicinal Chemistry (2009)
52, 2613-2617
|
156. | Timothy J. Cheeseright, Melanie Holm, Frank Lehmann, Sabine Luik, Marcia Göttert, James L. Melville, and Stefan Laufer*:
Novel lead structures for p38 MAP kinase via FieldScreen
virtual screening
| Journal of Medicinal Chemistry (2009)
52 (14): 4200-4209
|
157. | Bassam Abu Thaher, Pierre Koch, Dieter Schollmeyer and Stefan Laufer:
4-(2-(4-Fluorophenyl)furan-3-yl)pyridine
| Acta Cryst. (2009)
BT2859
E65, o458 |
158. | Bassam Abu Thaher, Pierre Koch, Dieter Schollmeyer and Stefan Laufer*:
4-(2-(4-Fluorophenyl)-1[H]-pyrrol-3-yl)pyridine
| Acta Cryst. (2009)
BT2858
E65, o457
|
159. | Pierre Koch, Dieter Schollmeyer and Stefan Laufer*:
4-(5-(4-Fluorophenyl)-1[H]-imidazol-4-yl)pyridine
| Acta Cryst. (2009)
IM2099
E65, o573
|
160. | CARSTEN HENNEGES, DINO BULLINGER, RICHARD FUX, NATASCHA FRIESE, HARALD SEEGER, HANS NEUBAUER, STEFAN LAUFER, CHRISTOPH H. GLEITER, MATTHIAS SCHWAB, ANDREAS ZELL, and BERND KAMMERER:
Prediction of breast cancer by profiling of urinary RNA metabolites using SVM-based feature selection | BMC Cancer (2009)
9:104
doi:10.1186/1471-2407-9-104
|
161. | HELGA JOOS, WOLFGANG ALBRECHT, STEFAN LAUFER and ROLF E. BRENNER:
Influence of p38MAPK inhibition on IL-1ß-stimulated human chondrocytes: A microarray approach
| INTERNATIONAL JOURNAL OF
MOLECULAR MEDICINE (2009)
23: 685-693
|
162. | Jean-Pierre Raynauld, Johanne Martel-Pelletier, François Abram, Marc Dorais, Boulos Haraoui, Denis Choquette, Peter Bias, Karl H Emmert, Stefan Laufer and Jean-Pierre Pelletier:
Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis
| ARTHRITIS RESEARCH & THERAPY (2008)
10: 6, R129
|
163. | Ernestina Saulle, Roberta Riccioni, Simona Coppola, Isabella Parolini, Daniela Diverio, Viviana Riti, Gualtiero Mariani, Stefan Laufer, Massimo Sargiacomo and Ugo Testa:
Colocalization of the VEGF-R2 and the common IL-3/GMCSF receptor beta chain to lipid rafts leads to enhanced p38 activation
| British Journal of Haematology (2009)
Volume 145 Issue 3, Pages
399 - 411
|
164. | Andy J. Liedtke, Peter R. W. E. F. Keck, Frank Lehmann, Andreas Koeberle, Oliver Werz and Stefan A. Laufer:
Arylpyrrolizines as Inhibitors of Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) or as Dual Inhibitors of mPGES-1 and 5-Lipoxygenase (5-LOX)
| Journal of Medicinal Chemistry (2009)
52 (15): 4968-4972
|
165. | Solveigh C. Karcher and Stefan A. Laufer*:
Successful Structure-based Design of Recent p38 MAP Kinase Inhibitors
| Curr. Top. Med. Chem.
(2009)
In Press
|
166. | Koch, P., Schollmeyer, D., Laufer, S.:
4-[3-(4-Fluorophenyl)quinoxalin-2-yl]-N-isopropylpyridin-2- amine
| Acta Cryst. (2009)
E65, o1344
|
167. | Jahns, H., Koch, P., Schollmeyer, D., Laufer, S.:
1-(2-(Benzylamino)pyridin-4-yl)-2-(4-fluorophenyl)ethane-1,2-dione
| Acta Cryst. (2009)
E65, o1451
|
168. | Jahns, H., Koch, P., Schollmeyer, D., Laufer, S.:
3-(4-Fluorophenyl)-6-methoxy-2-(pyridin-4-yl)quinoxaline | Acta Cryst. (2009)
E65, o1626
|
169. | Christian Peifer, Mohammed Abadleh, Joachim Bischof, Dominik Hauser, Verena Schattel, Heidrun Hirner, Uwe Knippschild and Stefan Laufer:
3,4-Diaryl-isoxazoles and -imidazoles as Potent Dual Inhibitors of p38α MAPK and CK1δ
| Journal of Medicinal Chemistry (2009)
In Press
|
170.
| Raynauld, J-P, Martel-Pelletier, J., Bias, P., Laufer, S., Haraoui, B., Choquette, D., Beaulieu, A. D., Abram, F., Dorais, M., Vignon, E., Pelletier, J-P:
Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in
knee osteoarthritis: a first multicentre clinical trial using quantitative MRI | ANNALS OF THE RHEUMATIC DISEASES
(2009)
Volume: 68 Issue: 6
Pages: 938-947 |
171.
| Philipp A. Lang , Ravi S. Kasinathan , Verena B. Brand, Christophe Duranton, Camelia Lang , Saisudha Koka, Ekaterina Shumilina, Daniela S. Kempe, Valerie Tanneur, Ahmad Akel, Karl S. Lang, Michael Föller, Jürgen F. J. Kun, Peter G. Kremsner, Sebastian Wesselborg, Stefan Laufer, Christoph S. Clemen, Claudia Herr, Angelika A. Noegel, Thomas Wieder, Erich Gulbins, Florian Lang, Stephan M. Huber:
Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency
| Cell Physiol Biochem
(2009)
2008MS051, accepted |
